KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Tax Provisions (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Tax Provisions for 16 consecutive years, with $104.0 million as the latest value for Q1 2026.

  • For Q1 2026, Tax Provisions rose 8.0% year-over-year to $104.0 million; the TTM value through Mar 2026 reached $733.5 million, up 51.27%, while the annual FY2025 figure was $725.8 million, 97.6% up from the prior year.
  • Tax Provisions hit $104.0 million in Q1 2026 for Regeneron Pharmaceuticals, down from $199.1 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $303.3 million in Q3 2025 and bottomed at -$21.3 million in Q1 2024.
  • Average Tax Provisions over 5 years is $115.5 million, with a median of $111.1 million recorded in 2022.
  • Year-over-year, Tax Provisions crashed 152.99% in 2024 and then surged 552.11% in 2025.
  • Regeneron Pharmaceuticals' Tax Provisions stood at $127.6 million in 2022, then tumbled by 109.4% to -$12.0 million in 2023, then surged by 436.67% to $40.4 million in 2024, then surged by 392.82% to $199.1 million in 2025, then crashed by 47.76% to $104.0 million in 2026.
  • According to Business Quant data, Tax Provisions over the past three periods came in at $104.0 million, $199.1 million, and $303.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.